FG-3019 For Idiopathic Pulmonary Fibrosis
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis | European Respiratory Society
DMD: start at I-Motion of trials with pamrevlumab in ambulatory and non-ambulatory patients - Institut de Myologie
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis | Arthritis Research & Therapy | Full Text
Potential Duchenne MD Fibrosis Therapy, Pamrevlumab, Named Orphan Drug by FDA
Summary scheme. FG-3019 attenuated proliferation and induced apoptosis... | Download Scientific Diagram
Pamrevlumab - Parent Project Muscular Dystrophy
Dose-dependence of target-mediated elimination of FG-3019. The percent... | Download Scientific Diagram
IPF Disease Management Strategies With an Update on Clinical Trials - ppt download
EX-99.1
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis | European Respiratory Society
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer | PNAS
The FG-3019 binding epitope overlaps with the VWC domain of connective... | Download Scientific Diagram
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer | PNAS
Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria | American Society of Nephrology
EX-99.1
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ESMO Open
Study FGCL-3019-079 Trial of FG-3019, a Monoclonal Antibody to Connective Tissue Growth Factor, i
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer | PNAS
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis | European Respiratory Society
FibroGen, Inc.
Effects of FG-3019 on CTGF expression and fibrosis. (A) CTGF expression... | Download Scientific Diagram
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Frontiers | Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension
FG-3019 ameliorates angiotensin II (Ang II)-induced skin fibrosis. a... | Download Scientific Diagram
